why choose us

First received: January 09, 2025

Clinical Trial: RITUXIMAB BS Intravenous Infusion 100mg?500mg [Pfizer] Post-marketing Database Study

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Lymphoma

Study Type: OBSERVATIONAL


Official Title: RITUXIMAB BS Intravenous Infusion 100mg?500mg [Pfizer] Post-marketing Database Study

Brief Summary: To evaluate the incidence of the outcomes for the safety specifications in patients of Medical Data Vision database in Japan diagnosed with CD20 positive B-cell non- Hodgkin's lymphoma who were treated with Rituximab Pfizer to compare it with outcomes in patients who were treated with Rituxan from 01 January 2020 through 31 December 2024

Read more